TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

15 Aug 2024 12:17:01 By Nasdaq GlobeNewswire

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

15 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

14 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

09 Aug 2024 11:00:00 By Nasdaq GlobeNewswire

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

11 Jul 2024 12:21:21 By Nasdaq GlobeNewswire

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

10 Jul 2024 08:05:00 By Nasdaq GlobeNewswire

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

08 Jul 2024 16:07:16 By Nasdaq GlobeNewswire

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

26 Jun 2024 12:46:13 By Nasdaq GlobeNewswire

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

25 Jun 2024 08:05:00 By Nasdaq GlobeNewswire

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

18 Jun 2024 15:17:05 By Nasdaq GlobeNewswire

Tevogen Bio Set to Join Russell 3000® Index

12 Jun 2024 15:45:00 By Nasdaq GlobeNewswire

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

11 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

07 Jun 2024 15:32:04 By Nasdaq GlobeNewswire

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

06 Jun 2024 18:14:31 By Nasdaq GlobeNewswire

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

06 Jun 2024 15:52:26 By Nasdaq GlobeNewswire

Tevogen Bio Reports First Quarter 2024 Financial Results

29 May 2024 08:00:00 By Nasdaq GlobeNewswire

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

16 May 2024 14:00:00 By Nasdaq GlobeNewswire

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

10 May 2024 17:40:49 By Nasdaq GlobeNewswire

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

01 May 2024 08:05:00 By Nasdaq GlobeNewswire

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

26 Apr 2024 09:23:59 By Nasdaq GlobeNewswire